9 completed, 2 active not recruiting, 2 unknown, 1 not yet recruiting. 16 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 16 | Completed 9, Active not recruiting 2, Unknown 2, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
Follow Meningitis, Meningococcal: new trials by email Literature Review of Meningitis, Meningococcal trials Research Report on Meningitis, Meningococcal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 Years MPSV-ACYW - Meningococcal Disease; Meningococcal Meningitis | Phase 4 | Not yet recruiting | Zhejiang Provincial Center for Disease Control and Prevention | 200 | 2026-10-20 | 2026-10-21 |
| Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons Serogroup B meningococal vaccine - Meningococcal Meningitis, Serogroup B, Transgender Persons | Phase 4 | Recruiting | University Ghent | 250 | 2025-01-31 | 2026-01-20 |
| Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants MCV4 - Epidemic Meningitis | Phase 4 | Completed | CanSino Biologics Inc. | 3011 | 2024-06-12 | 2026-08-13 |
| A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age rMenB+OMV NZ - Meningitis, Meningococcal | Phase 4 | Active not recruiting | GlaxoSmithKline | 50 | 2023-11-10 | 2026-04-06 |
| Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) MCV4 - Epidemic Meningitis | Phase 4 | Active not recruiting | CanSino Biologics Inc. | 660 | 2023-09-20 | 2026-03-04 |
| A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years Yuxi Walvax MPV ACYW® vaccine, Sanofi Pasteur Menactra® vaccine - Neisseria Meningitides Meningitis | Phase 4 | Completed | Walvax Biotechnology Co., Ltd. | 260 | 2020-12-23 | 2023-07-07 |
| Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018 Ciprofloxacin - Meningitis, Meningococcal | Phase 4 | Withdrawn | Epicentre | 2019-03-01 | 2019-08-14 | |
| Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population Bexsero® (meningitis B vaccine), Menveo® (meningitis ACWY vaccine) - Hiv, Meningitis, Meningococcal | Phase 4 | Unknown | St George's, University of London | 55 | 2019-02-21 | 2019-04-10 |
| A Sourcing Study to Collect Human Blood Samples From Healthy Adults rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) - Meningitis, Meningococcal | Phase 4 | Completed | GlaxoSmithKline | 1021 | 2018-03-08 | 2023-07-17 |
| Ciprofloxacin for the Prevention of Meningococcal Meningitis Ciprofloxacin - Meningitis, Meningococcal | Phase 4 | Completed | Epicentre | 300 | 2017-04-22 | 2018-02-08 |
| Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 1311 | 2016-07-21 | 2022-04-25 |
| Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 110 | 2015-12-01 | 2016-11-07 |
| Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Meningitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 60 | 2015-10-20 | 2017-11-06 |
| A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine - Meningococcal Meningitis | Phase 4 | Completed | Novartis | 801 | 2011-09-01 | 2014-02-14 |
| Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine A, C, Y, W135 meningococcal polysaccharide vaccine - Infections, Meningococcal, Meningitis, Meningococcic | Phase 4 | Completed | Epicentre | 720 | 2004-06-01 | 2006-12-22 |
| Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine · Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose) - Meningococcal Disease; Meningococcal Meningitis | Phase 4 | Unknown | Chiron Corporation | 264 | 2003-09-01 | 2005-12-06 |
Meningococcal Infections (8) · Meningitis (7) · Acquired Immunodeficiency Syndrome (1) · Coitus (1) · HIV Infections (1) · Tetanus (1) · Vaccine-Preventable Diseases (1) · Whooping Cough (1)
Bacterial Infections (16) · Bacterial Infections and Mycoses (16) · Central Nervous System Bacterial Infections (16) · Central Nervous System Diseases (16) · Central Nervous System Infections (16) · Gram-Negative Bacterial Infections (16) · Infections (16) · Meningitis, Bacterial (16) · Neisseriaceae Infections (16) · Nervous System Diseases (16) · Neuroinflammatory Diseases (16) · Meningitis (9) · Meningococcal Infections (8) · Behavior (1) · Blood-Borne Infections (1)
Meningococcal Vaccines (5) · 4CMenB vaccine (3) · Ciprofloxacin (2) · MenACWY (1) · serogroup C meningococcal conjugate vaccine (1)
Epicentre (3) · Sanofi Pasteur, a Sanofi Company (3) · CanSino Biologics Inc. (2) · GlaxoSmithKline (2) · Chiron Corporation (1) · Novartis (1) · St George's, University of London (1) · University Ghent (1) · Walvax Biotechnology Co., Ltd. (1) · Zhejiang Provincial Center for Disease Control and Prevention (1)
China (2) · Niger (2) · South Korea (2) · United Kingdom (2) · United States (2) · Australia (1) · Belgium (1) · Germany (1) · Italy (1) · Japan (1) · Mali (1) · Norway (1) · Uganda (1)
Andrew J. Pollard, MBBS, FRCPCH, PhD (1) · Catherine Cosgrove, MBBS PhD (1) · Dominique A Caugant, PhD (1) · Philippe J Guerin, MD, MPH, PhD (1) · Prof. Dr. Isabel Leroux-Roels, PhD, MD (1) · Rebecca F Grais, PhD (1) · Samba O Sow, MD, MSc (1)
PMID 19048025, PMID 28646924, PMID 29944651, PMID 31377946, PMID 33439463, PMID 37088964, PMID 37401618
2017 (1)